U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H21Cl2FN4O
Molecular Weight 471.354
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-394136

SMILES

CC1=C([C@H](N2N=CC=C2N1)C3=CC=C(Cl)C(Cl)=C3)C(=O)N4CCC[C@H]4C5=CC=C(F)C=C5

InChI

InChIKey=LADJRPDOKVCQCG-NZQKXSOJSA-N
InChI=1S/C24H21Cl2FN4O/c1-14-22(24(32)30-12-2-3-20(30)15-4-7-17(27)8-5-15)23(31-21(29-14)10-11-28-31)16-6-9-18(25)19(26)13-16/h4-11,13,20,23,29H,2-3,12H2,1H3/t20-,23+/m0/s1

HIDE SMILES / InChI

Description

Bristol-Myers Squibb developed BMS-394136, as a selective IKur inhibitor for the treatment of arrhythmias. IKur is a repolarizing K+ current encoded by the KCNA5 gene and is expressed predominantly in the atrium of human. IKur is a potential atrial-selective target for the treatment of atrial fibrillation. Atrial selectivity and safety of BMS-394136 were studied in phase I clinical trial in patients with heart diseases. However, further, development has been discontinued.

Originator

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
Oral Solution, Oral, 100 mg, Single dose, 1 day.
Route of Administration: Oral